Bausch + Lomb completes ISTA acquisition

Bausch + Lomb (B + L) has completed its acquisition of ISTA Pharmaceuticals Inc.

Madison, NJ-Bausch + Lomb (B + L) has completed its acquisition of ISTA Pharmaceuticals Inc.

According to B + L, the addition of ISTA bolsters its product portfolio and pipeline, increasing the company’s therapeutic offerings for physicians and their patients and creating opportunity for growth.

“The addition of ISTA creates exciting new opportunities for B + L’s rapidly growing pharmaceutical business,” said Daniel M. Wechsler, executive vice president and president, B + L Global Pharmaceuticals. “ISTA is an exceptional company with strong formulation expertise, a robust portfolio of therapeutic offerings, and a promising pipeline. And, importantly, our new colleagues from ISTA share our passion for innovation and delivering products that will help patients see better and improve the quality of their lives.”

The all-cash transaction, valued at approximately $500 million, is expected to add more than $150 million to B + L’s annualized sales and be accretive to the company’s earnings before interest, taxes, depreciation, and amortization this year.

B + L is providing a list of frequently asked questions and answers regarding the acquisition, which can be found atwww.bausch.com/en/Our-Company/Recent-News/Frequently-Asked-Questions.

For more articles in this issue of Ophthalmology Times eReport, click here.